Novel inhibitor design for hemagglutinin against H1N1 influenza virus by core hopping method

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Li, Xiao Bo ^a   Wang, Shu Qing ^a,b   Xu, Wei Ren ^c   Wang, Run Ling ^a   Chou, Kuo Chen ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b GORDON LIFE SCIENCE INSTITUTE   (United States)

^c TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ARGININE; ASPARAGINE; GLUTAMINE; INFLUENZA VIRUS HEMAGGLUTININ; NEO 6; PROLINE; UNCLASSIFIED DRUG; ZINC 01602230;

ALGORITHM; ARTICLE; BINDING AFFINITY; BINDING SITE; CORE HOPPING; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG STRUCTURE; HYDROGEN BOND; INFLUENZA VIRUS A H1N1; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING;

ALGORITHMS; ANTIVIRAL AGENTS; BINDING SITES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; USER-COMPUTER INTERFACE;

EID: 82455181447     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028111     Document Type: Article

References (58)

1. Naffakh N, van der Werf S, (2009) April 2009: an outbreak of swine-origin influenza A(H1N1) virus with evidence for human-to-human transmission. Microbes and infection/Institut Pasteur 11: 725-728.
2. Uchida M, Tsukahara T, Kaneko M, Washizuka S, Kawa S, (2011) Swine-origin influenza a outbreak 2009 at Shinshu University, Japan. BMC public health 11: 79.
3. Cheng PK, To AP, Leung TW, Leung PC, Lee CW, et al. (2009) Oseltamivir- and amantadine-resistant influenza virus A (H1N1). Emerg Infect Dis 16: 155-156.
4. Wang T, Wade RC, (2001) Comparative binding energy (COMBINE) analysis of influenza neuraminidase-inhibitor complexes. J Med Chem 44: 961-971.
5. Schnell JR, Chou JJ, (2008) Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451: 591-595.
6. Pielak RM, Schnell JR, Chou JJ, (2009) Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc Natl Acad Sci U S A 106: 7379-7384.
7. Du QS, Huang RB, Wang CH, Li XM, Chou KC, (2009) Energetic analysis of the two controversial drug binding sites of the M2 proton channel in influenza A virus. J Theor Biol 259: 159-164.
8. Wang JF, Chou KC, (2010) Insights from studying the mutation-induced allostery in the M2 proton channel by molecular dynamics. Protein Eng Des Sel 23: 663-666.
9. Wei H, Wang CH, Du QS, Meng J, Chou KC, (2009) Investigation into adamantane-based M2 inhibitors with FB-QSAR. Med Chem 5: 305-317.
10. Kolocouris N, Zoidis G, Foscolos GB, Fytas G, Prathalingham SR, et al. (2007) Design and synthesis of bioactive adamantane spiro heterocycles. Bioorg Med Chem Lett 17: 4358-4362.
11. Schauer R, (2000) Achievements and challenges of sialic acid research. Glycoconj J 17: 485-499.
12. Varki NM, Varki A, (2007) Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab Invest 87: 851-857.
13. Ward CW, Dopheide TA, (1981) Amino acid sequence and oligosaccharide distribution of the haemagglutinin from an early Hong Kong influenza virus variant A/Aichi/2/68 (X-31). Biochem J 193: 953-962.
14. Akten ED, Cansu S, Doruker P, (2009) A Docking Study Using Atomistic Conformers Generated Via Elastic Network Model for Cyclosporin a/Cyclophilin a Complex,. Journal of Biomolecular Structure & Dynamics 13.
15. De Clercq E, (2006) Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 5: 1015-1025.
16. McKimm-Breschkin JL, (2000) Resistance of influenza viruses to neuraminidase inhibitors-a review. Antiviral Res 47: 1-17.
17. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667-2672.
18. Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, et al. (2007) Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J Virol 81: 12418-12426.
19. Boni MF, (2008) Vaccination and antigenic drift in influenza. Vaccine 26 (Suppl 3): C8-14.
20. McDonald NJ, Smith CB, Cox NJ, (2007) Antigenic drift in the evolution of H1N1 influenza A viruses resulting from deletion of a single amino acid in the haemagglutinin gene. J Gen Virol 88: 3209-3213.
21. Hartshorn KL, Liou LS, White MR, Kazhdan MM, Tauber JL, et al. (1995) Neutrophil deactivation by influenza A virus. Role of hemagglutinin binding to specific sialic acid-bearing cellular proteins. J Immunol 154: 3952-3960.
22. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, et al. (2005) Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. Journal of virology 79: 2814-2822.
23. Zhang W, Qi J, Shi Y, Li Q, Gao F, et al. (2010) Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus. Protein Cell 1: 459-467.
24. Chou KC, (2004) Structural bioinformatics and its impact to biomedical science. Curr Med Chem 11: 2105-2134.
25. Chou KC, (2004) Molecular therapeutic target for type-2 diabetes. Journal of Proteome Research 3: 1284-1288.
26. Wang JF, Chou KC, (2011) Insights from modeling the 3D structure of New Delhi metallo-beta-lactamase and its binding interactions with antibiotic drugs. PLoS ONE 6: e18414.
27. Chou KC, Wei DQ, Zhong WZ, (2003) Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem Biophys Res Commun 308: 148-151.
28. Sirois S, Wei DQ, Du QS, Chou KC, (2004) Virtual Screening for SARS-CoV Protease Based on KZ7088 Pharmacophore Points. J Chem Inf Comput Sci 44: 1111-1122.
29. Chou KC, Shen HB, (2008) ProtIdent: A web server for identifying proteases and their types by fusing functional domain and sequential evolution information. Biochem Biophys Res Comm 376: 321-325.
30. Chou KC, (1993) A vectorized sequence-coupling model for predicting HIV protease cleavage sites in proteins. Journal of Biological Chemistry 268: 16938-16948.
31. Chou KC, (1996) Review: Prediction of HIV protease cleavage sites in proteins. Analytical Biochemistry 233: 1-14.
32. Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, et al. (2002) The Protein Data Bank. Acta Crystallogr D Biol Crystallogr 58: 899-907.
33. Schrödinger-LLC (2009) Schrödinger Suite 2009, Virtual Screening Workflow; Glide version 5.5, Schrödinger, LLC, New York, NY, 2009.
34. Goodford PJ, (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28: 849-857.
35. Del Carpio CA, Takahashi Y, Sasaki S, (1993) A new approach to the automatic identification of candidates for ligand receptor sites in proteins: (I). Search for pocket regions. J Mol Graph 11: 23-29, 42.
36. Hendlich M, Rippmann F, Barnickel G, (1997) LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins. J Mol Graph Model 15: 359-363, 389.
37. Chou KC, Watenpaugh KD, Heinrikson RL, (1999) A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator. Biochemical and biophysical research communications 259: 420-428.
38. Irwin JJ, Shoichet BK, (2005) ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 45: 177-182.
39. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47: 1739-1749.
40. Banks JL, Beard HS, Cao Y, Cho AE, Damm W, et al. (2005) Integrated Modeling Program, Applied Chemical Theory (IMPACT). J Comput Chem 26: 1752-1780.
41. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP, (1997) Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 11: 425-445.
42. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47: 1750-1759.
43. Liao QH, Gao QZ, Wei J, Chou KC, (2011) Docking and Molecular Dynamics Study on the Inhibitory Activity of Novel Inhibitors on Epidermal Growth Factor Receptor (EGFR). Medicinal Chemistry 7: 24-31.
44. Cai L, Wang Y, Wang JF, Chou KC, (2011) Identification of Proteins Interacting with Human SP110 During the Process of Viral Infections. Medicinal Chemistry 7: 121-126.
45. Chou KC, Wei DQ, Du QS, Sirois S, Zhong WZ, (2006) Progress in computational approach to drug development against SARS. Curr Med Chem 13: 3263-3270.
46. Wei H, Zhang R, Wang C, Zheng H, Li A, et al. (2007) Molecular insights of SAH enzyme catalysis and implication for inhibitor design. J Theor Biol 244: 692-702.
47. Chou KC, (1984) The biological functions of low-frequency phonons: 3. Helical structures and microenvironment. Biophysical Journal 45: 881-890.
48. Wang JF, Chou KC, (2009) Insight into the molecular switch mechanism of human Rab5a from molecular dynamics simulations. Biochem Biophys Res Commun 390: 608-612.
49. Chou KC, (1989) Low-frequency resonance and cooperativity of hemoglobin. Trends in Biochemical Sciences 14: 212.
50. Chou KC, (1984) The biological functions of low-frequency phonons: 4. Resonance effects and allosteric transition. Biophysical Chemistry 20: 61-71.
51. Chou KC, (1987) The biological functions of low-frequency phonons: 6. A possible dynamic mechanism of allosteric transition in antibody molecules. Biopolymers 26: 285-295.
52. Chou KC, Mao B, (1988) Collective motion in DNA and its role in drug intercalation. Biopolymers 27: 1795-1815.
53. Chou KC, Zhang CT, Maggiora GM, (1994) Solitary wave dynamics as a mechanism for explaining the internal motion during microtubule growth. Biopolymers 34: 143-153.
54. Chou KC, (1988) Review: Low-frequency collective motion in biomacromolecules and its biological functions. Biophysical Chemistry 30: 3-48.
55. Oostenbrink C, Soares TA, van der Vegt NF, van Gunsteren WF, (2005) Validation of the 53A6 GROMOS force field. Eur Biophys J 34: 273-284.
56. Schuttelkopf AW, van Aalten DM, (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60: 1355-1363.
57. Stevens J, Corper AL, Basler CF, Taubenberger JK, Palese P, et al. (2004) Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 303: 1866-1870.
58. Chang TT, Sun MF, Chen HY, Tsai FJ, Fisher M, et al. (2011) Novel hemagglutinin inhibitors for H1N1 influenza virus screening from TCM database. Molecular Simulation 37: 361-368.